KORU Medical Systems (KRMD) CFO buys 5,500 shares in open market

Rhea-AI Filing Summary

KORU Medical Systems, Inc. Chief Financial Officer Thomas Edward Adams bought additional company stock in the open market. He purchased a total of 5,500 shares of common stock in two open-market transactions, paying $3.90 and $3.86 per share.

Insider Trade Summary

Net Buyer: 5,500 shares ($21,248)

Net Buy 2 txns

Insider Adams Thomas Edward

Role Chief Financial Officer

Bought 5,500 shs ($21K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,041	$3.86	$19K
Purchase	Common Stock	459	$3.90	$2K

Holdings After Transaction: Common Stock — 307,688 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased (trade 1): 459 shares Price per share (trade 1): $3.90/share Shares purchased (trade 2): 5,041 shares +2 more

5 metrics

Shares purchased (trade 1) 459 shares Open-market purchase of common stock at $3.90 per share

Price per share (trade 1) $3.90/share Open-market purchase of 459 common shares

Shares purchased (trade 2) 5,041 shares Open-market purchase of common stock at $3.86 per share

Price per share (trade 2) $3.86/share Open-market purchase of 5,041 common shares

Total shares bought 5,500 shares Net open-market purchases reported in transaction summary

Key Terms

open-market purchase, non-derivative, Form 4, transaction code P

4 terms

open-market purchase financial

"transaction_action: "open-market purchase" for both common stock trades"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

non-derivative financial

"transaction_type is "non-derivative" for both common stock transactions"

Form 4 regulatory

"INSIDER FILING DATA (Form 4) describes the CFO’s transactions"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

transaction code P financial

"transaction_code: "P" with description "Purchase in open market or private transaction""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Adams Thomas Edward

(Last) (First) (Middle)

C/O KORU MEDICAL SYSTEMS, INC.

100 CORPORATE DRIVE

(Street)

MAHWAH NEW JERSEY 07430

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KORU Medical Systems, Inc. [ KRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		P		5,041	A	$3.86	307,688	D
Common Stock	05/14/2026		P		459	A	$3.9	308,147	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person.

	/s/ Thomas Edward Adams	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did KRMD CFO Thomas Edward Adams report?

Thomas Edward Adams reported buying KORU Medical Systems common stock. He executed two open-market purchases totaling 5,500 shares, showing additional personal exposure to KRMD equity at prices between $3.86 and $3.90 per share.

How many KORU Medical Systems (KRMD) shares did the CFO buy?

The CFO bought 5,500 KRMD common shares. The Form 4 shows two separate open-market purchases, one for 459 shares and another for 5,041 shares, both executed on the same transaction date.

At what prices did the KRMD CFO purchase company shares?

The CFO paid $3.90 and $3.86 per share for KRMD stock. These prices reflect two open-market transactions in KORU Medical Systems common stock reported in the Form 4 filing for the same transaction date.

What type of transactions were reported in this KRMD Form 4?

All reported transactions were open-market purchases of common stock. The filing classifies both entries as non-derivative transactions with code P, indicating standard open-market or private purchase activity rather than option exercises or derivative conversions.

Does the KRMD Form 4 show any stock sales by the CFO?

The Form 4 does not show any stock sales by the CFO. It reports two open-market purchases totaling 5,500 common shares, with no dispositions, gifts, tax withholdings, or derivative exercises listed in the transaction summary.